Atopic Dermatitis
The Atopic Dermatitis pipeline: 107 tracked drugs, 11 approved for this indication.
11 approved / phase 420 Phase 348 Phase 25 Phase 1/219 Phase 14 preclinical / unstaged
Compare the share prices of listed companies in Atopic Dermatitis →
Total attributable cost
$98.8B
$4,979/patient
Drug spend
$23.2B
$1,168/patient
All severities, self-reported diagnosis (2024 NHIS) · US
The Atopic Dermatitis pipeline
Key trial results for every approved and late-stage drug: Atopic Dermatitis results by drug.